Very Low Density Lipoprotein (VLDL) Available to Researchers from Lee Biosolutions

ST. LOUIS – Lee Biosolutions has announced the production and availability of very low density lipoprotein (VLDL) from human plasma for purchase at LeeBio.com.

Very low density lipoprotein contains about 16%-22% cholesterol and high amounts of triglycerides, which can put people at risk for coronary heart disease. VLDL levels have also been correlated with accelerated rates of atherosclerosis, and are elevated in a number of other diseases and metabolic states.

According to Lee Biosolutions President Burton Lee, the company’s recent addition of VLDL to their product line is an extension of their commitment to providing the latest materials in demand by the research community.

“We constantly keep an ear tuned to our customers and to the international research community as a whole,” Lee said. “This helps us stay on top of the latest trends in research and assures that we’re ready when we’re called on to deliver.”

Very low density lipoproteins inhibit DNA synthesis in lymphocytes activated by the nonspecific mitogen concanavalin A (Con A). VLDL is the next step down from chylomicrons in terms of size and lipid content.
VLDL circulates through the blood giving up triglycerides to fat and muscle tissue until the VLDL remnants are modified and converted into LDL. The lipoprotein is produced in the liver.

According to the company, The VLDL donors are of US origin and have been tested and found to be negative for HbsAg, HCV, HIV-1 & 2, Syphilis and HIV-1 Antigen by currently approved FDA methods.

Lee Biosolutions is a leader in the biomaterials industry, providing the quality biomaterial products to clinical labs and researchers around the world, developing tomorrow’s cures. The company has provided the materials used in a number of high profile biomarker studies. For more information or to place an order, contact Lee Biosolutions at 314-968-1091, or visit the company’s website, www.leebio.com.